Compare NBIX & ASND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | ASND |
|---|---|---|
| Founded | 1992 | 2006 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 15.2B |
| IPO Year | 1996 | 2014 |
| Metric | NBIX | ASND |
|---|---|---|
| Price | $172.01 | $260.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 22 | 16 |
| Target Price | $180.91 | ★ $281.50 |
| AVG Volume (30 Days) | ★ 1.1M | 704.2K |
| Earning Date | 05-05-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.95 | N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $161,626,000.00 | N/A |
| Revenue This Year | $24.73 | $96.35 |
| Revenue Next Year | $13.14 | $44.91 |
| P/E Ratio | $89.54 | ★ N/A |
| Revenue Growth | ★ 977.51 | N/A |
| 52 Week Low | $122.14 | $161.09 |
| 52 Week High | $181.18 | $282.15 |
| Indicator | NBIX | ASND |
|---|---|---|
| Relative Strength Index (RSI) | 56.82 | 55.04 |
| Support Level | $153.96 | $213.28 |
| Resistance Level | N/A | $282.15 |
| Average True Range (ATR) | 4.57 | 8.03 |
| MACD | -0.61 | -0.92 |
| Stochastic Oscillator | 49.24 | 15.77 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.